PE-22-28 Dosing Protocol: Neuroplasticity Guide
Also known as: TREK-1 Inhibitor Heptapeptide, Spadin Analog
Studied in published research — not a medical recommendation. Primary protocol (Cognitive/Antidepressant Protocol): 100-500 mcg, Daily or twice daily.
Daily or twice daily
Research-reported range (no primary dosing study). Preclinical studies show rapid antidepressant effects
Subcutaneous injection or intranasal
Published peer-reviewed research & clinical protocols
No verified human half-life on file for this compound
A vial is powder until you add bacteriostatic water. Change the vial size or water volume below to see the exact unit mark on your syringe.
All U-100: 100 units = 1 mL. 50 doses in the vial at the low end (10 doses at the high end).
Save PE-22-28 (Mini-Spadin) to your personal protocol list to log your custom dosage, syringe units, ON/OFF cycle dates, and lab notes across devices.
PE-22-28 (Mini-Spadin) supplier & $/mg comparison.
At a Glance · 2026 FDA / 503A / WADA / Evidence Profile
What is a Nootropic Peptide?
A peptide that enhances cognitive function — memory, focus, learning, or neuroprotection. Unlike synthetic nootropics (racetams, modafinil), peptide nootropics work through neurotrophic factors like BDNF and NGF. Examples: Semax, Selank, Dihexa, PE-22-28. Most were developed in Russian neuroscience labs.
EDUCATIONAL AND RESEARCH REFERENCE ONLY — NOT MEDICAL ADVICE. PE-22-28 (Mini-Spadin) is not FDA approved for human use (unless specified above). This information does not constitute medical advice.
Overview
PE-22-28 is a synthetic peptide derived from the neuroprotective drug tianeptine. It represents the active pharmacophore responsible for tianeptine's neuroplasticity-enhancing effects.
Mechanisms of Action
- Modulates glutamate receptor activity (AMPA/NMDA)
- Enhances brain-derived neurotrophic factor (BDNF) expression
- Promotes neuroplasticity and synaptic remodeling
- Fast-acting antidepressant-like effects
Research Protocols
Summaries of published research. For educational purposes only.
| Protocol Name | Source | Dose | Frequency | Duration | Route | Evidence | Link | Save |
|---|---|---|---|---|---|---|---|---|
| Cognitive/Antidepressant Protocol | reported protocol | 100-500 mcg | Daily or twice daily | 4-8 weeks | Subcutaneous injection or intranasal | animal | — |
Systemic Inflammation, Tissue Repair & Immune Biomarker Panel (PE-22-28 (Mini-Spadin))
Objective inflammatory, hematologic, and trace-mineral markers to quantify connective-tissue recovery, cytokine resolution, and organ safety.
hs-CRP (High-Sensitivity C-Reactive Protein)
Day 0 + Wk 6–8Why track at baseline: Quantifies baseline systemic IL-6/NF-κB inflammatory burden from tendon, joint, gut, or vascular injury.
Week 6–8 check: Target <1.0 mg/L (optimal <0.5 mg/L) by Week 6–8 as tissue inflammation resolves.
ESR (Sedimentation Rate) & Ferritin
Day 0 + Wk 6–8Why track at baseline: Tracks chronic connective-tissue and autoimmune/mucosal inflammatory activity alongside iron stores.
Week 6–8 check: Downward trend in ESR confirming structural resolution rather than temporary analgesic masking.
CBC with Differential (WBC, Neutrophil/Lymphocyte Ratio)
Day 0 + Wk 6–8Why track at baseline: Evaluates innate/adaptive immune balance (especially for Thymosin Alpha-1, Thymosin Beta-4, LL-37 & KPV).
Week 6–8 check: Balanced lymphocyte count and improved Neutrophil-to-Lymphocyte Ratio (NLR 1.2–2.0).
CMP (Liver/Kidney) + Serum Copper & Zinc Ratio
Day 0 + Wk 6–8Why track at baseline: Verifies baseline hepatic/renal function and checks Copper:Zinc balance before GHK-Cu / GLOW / KLOW protocols.
Week 6–8 check: Maintain 1:1 to 1.2:1 Zinc-to-Copper equilibrium and normal transaminases/creatinine.
Related Studies
Despite the large number of available studies, a high clinical, statistical, and methodological heterogeneity was observed. More methodologically rigorous studies are needed to clarify the effectiveness of each protocol and modality of intervention.
Limitations: No placebo control reported. Review article — no new primary data.
From 89 studies (mean follow-up: 5.2 years), conversion risk was 41.5% (38.3%-44.7%) in clinical and 27.0% (22.0%-32.0%) in population-based studies, with Alzheimer's dementia as the most common outcome. Stability rates were 49.3% (clinical) and 49.8% (population).
Limitations: Animal study only — human translation uncertain. Review article — no new primary data.
Novel function of TREK-1 in regulating adipocyte differentiation and lipid accumulation.
Animal StudyFinally, our findings revealed that mice lacking TREK-1 gained more fat mass and had worse glucose tolerance when fed a high-fat diet (HFD) compared to the wild-type controls. The findings demonstrate that increase of the membrane potential at adipocytes through the downregulation of TREK-1 can influence the progression of adipogenesis.
Limitations: Animal study only — human translation uncertain.
The Italian guideline on diagnosis and treatment of dementia and mild cognitive impairment.
Human StudyThe literature review for this guideline included studies published up to November 2023. More than 1000 peer-reviewed publications were included, covering the following.
Limitations: No placebo control reported.
The CCDDs using a Minimum Core Test (MCT) significantly increased from 45.7% in 2015 to the current 57.1%. Territorial CCDDs using MCT significantly increased from 24.9% in 2015 to 37% in 2022 (p = 0.004).
Limitations: No placebo control reported.
Sortilin-derived peptides promote pancreatic beta-cell survival through CREB signaling pathway.
Animal StudyIn addition, Mini-Spadin promotes beta-cell proliferation, suggesting its possible regenerative effect. This study highlights new possible roles of PE in pancreatic beta-cell survival and its derivatives as pharmacological tools against diabetes.
Limitations: Animal study only — human translation uncertain.
Finally, enhanced neurogenesis and synaptogenesis contributed to the beneficial effects of mini-spadin against stroke and PSD. This work reveals the first evidence that the modulation of TREK-1 channels in the early and chronic phases of stroke as well as the stimulation of brain plasticity by mini-spadin could play a key role in its brain protective effects against stroke and its deleterious consequences such as PSD.
Limitations: No placebo control reported.
Shortened spadin analogs present increased inhibition potency for TREK-1, an improved AD activity, and prolonged in vivo bioavailability. Finally, we also discuss about other inhibitors of TREK-1 channels with a proven efficacy in treating depression in the clinic, such as fluoxetine.
Limitations: No placebo control reported. Review article — no new primary data.
Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity.
Animal StudyFinally, the action duration of PE 22-28 and its analogs was largely improved in comparison with that of spadin, up to 23 h instead of 7 h. Taken together, our results demonstrated that PE 22-28 and its derivatives represent other promising molecules that could be an alternative to spadin in the treatment of depression.
Limitations: Animal study only — human translation uncertain.
Sortilin derived propeptide regulation during adipocyte differentiation and inflammation.
Animal StudyAs a putative bioactive peptide, we have evaluated its autocrine effect by the use of spadin on 3T3-L1 adipocytes by performing glucose uptake and signalling experiments. Any effect was measured on adipocytes indicating that the use of spadin as an antidepressant would have no side effects on adipocyte physiology.
Limitations: Animal study only — human translation uncertain.
Community Outcomes
Community Data Coming Soon
Aggregate community outcomes will be displayed here once we have more reports. Be one of the first to share your experience!
Outcomes are self-reported and unverified. They represent individual experiences and may not reflect typical results.
Important Warnings
- •Limited safety data; research use only
- •May affect mood significantly - use with caution
- •Not FDA approved
Where to get PE-22-28 (Mini-Spadin), baseline labs & clinician oversight.
Ascension Peptides (US Vials)
MZ Biolabs & SafeCert COA-verified US domestic single vials with 50% off auto-applied for new customers.
SwissChems & Limitless Biotech
Same-day US domestic lyophilized vials, oral capsules, and endotoxin-screened nasal sprays (15% off Limitless w/ code PEPTIDEPROTOCOLS).
Superpower Labs & 503A Telehealth
Bloodwork, not a vial store. Get a baseline panel (100+ Quest biomarkers: metabolic, lipids, hormones, inflammation, kidney/liver) before you start a peptide protocol, then retest mid-cycle to see what actually changed.
Where to buy PE-22-28 (Mini-Spadin): best verified price
Prices checked Nov 11, 2026 · sorted by $/mg · RUO
- 1. Elite Research USA — $6.00/mg (10mg vial, $60.00)
- 2. Pure Peptides — $6.00/mg (5mg vial, $30.00)
- 3. Core Peptides — $6.75/mg (8mg vial, $54.00)
Where is the cheapest place to buy PE-22-28 (Mini-Spadin)?
As of Nov 11, 2026, the lowest verified US domestic single-vial price we found is Elite Research USA at $6.00/mg (10mg vial, $60.00). We compared 5 US suppliers with live, checked prices.
How much does PE-22-28 (Mini-Spadin) cost per mg?
Verified US domestic prices currently range from $6.00/mg to $12.00/mg depending on supplier and vial size. Larger vials usually lower the $/mg.
How are these prices verified?
Each price is read from the supplier's own product page or store data and divided by the vial's mg. Suppliers we could not verify are left out rather than estimated. Tables sort strictly by $/mg, never by partner status. Prices are re-checked weekly on our price index.
Is PE-22-28 (Mini-Spadin) approved for human use?
Products from these suppliers are sold for laboratory research use only (RUO). This page is an educational price reference, not medical advice.
All compounds $/mgWeekly $/mg price indexReconstitution calculatorFree cheat sheet
Peptide Reconstitution & U-100 Syringe Cheat Sheet
Printable U-100 insulin syringe draw chart for 5mg–50mg vials, plus our weekly $/mg price-drop brief.
Trusted Voices
X/Twitter accounts discussing this peptide
Related Peptides
More cognitive peptides
Semax
Semax is a synthetic peptide derived from adrenocorticotropi...
Selank
Selank is a synthetic peptide derived from tuftsin. It has b...
Noopept (Omberacetam)
Noopept is a synthetic nootropic dipeptide developed in Russ...
Dihexa
Dihexa is a synthetic peptide derived from angiotensin IV th...
Cerebrolysin
Cerebrolysin is a porcine brain-derived peptide preparation ...
Vendor vs vendor: price per mg
Head-to-head $/mg on shared compounds. Prices verified Nov 11, 2026.
- Ascension vs SwissChems (3 shared compounds)
- Elite vs SwissChems (3 shared compounds)
- Elite vs Ascension (26 shared compounds)
- Protide vs SwissChems (3 shared compounds)
- Protide vs Ascension (6 shared compounds)
- Ameano vs SwissChems (3 shared compounds)
- Ameano vs Ascension (4 shared compounds)
- Swift vs Ascension (23 shared compounds)
- BioLongevity vs Ascension (16 shared compounds)
- Peptyes vs SwissChems (3 shared compounds)
- Peptyes vs Elite (20 shared compounds)
- Peptyes vs Swift (17 shared compounds)
- Peptyes vs Pure (17 shared compounds)
- Peptyes vs Ascension (20 shared compounds)
Compound vs compound: BPC-157 vs TB-500 · Tirzepatide vs Semaglutide · Retatrutide vs Tirzepatide · Wolverine Blend vs GLOW Blend · Semax vs Selank · KLOW Blend vs GLOW Blend · MOTS-c vs SS-31 · Sermorelin vs Ipamorelin · Retatrutide vs Semaglutide · Tesamorelin vs Sermorelin · All compounds $/mg →
Common questions
How many peptides are in the database?
100 compound pages, each with dosing references, reconstitution math and price per mg where a verified vendor price exists.
Where can I compare peptide prices?
Each compound page shows verified $/mg by vendor; the vendor-vs-vendor pages above compare two vendors across their shared compounds.